DesHis1Glu9-glucagon-[mPEG] and desHis 1Glu9(Lys30PAL)-glucagon: Long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity

European Journal of Pharmacology

Volumn 709, Issue 1-3, 2013, Pages 43-51

  Irwin, Nigel ^a   Franklin, Zara J ^a   O'Harte, Finbarr P M ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Glucagon Antagonist Insulin secretion High fat feeding ob ob mice PEGylation Fatty acid derivatisation

Indexed keywords

CYCLIC AMP; GLUCAGON DERIVATIVE; GLUCAGON RECEPTOR; GLUCOSE; GLUTAMIC ACID; HISTIDINE; INSULIN; LYSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME SYNTHESIS; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ACYLATION; ANIMALS; CELL LINE; CYCLIC AMP; DIPEPTIDYL PEPTIDASE 4; DRUG STABILITY; GLUCAGON; HEK293 CELLS; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; MICE, OBESE; OBESITY; POLYETHYLENE GLYCOLS; RECEPTORS, GLUCAGON; RECOMBINANT PROTEINS; SECOND MESSENGER SYSTEMS;

EID: 84877068508     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.03.041     Document Type: Article

References (37)

1. J.I. Bagger, F.K. Knop, J.J. Holst, and T. Vilsbøll Glucagon antagonism as a potential therapeutic target in type 2 diabetes Diabetes Obes. Metab. 13 2011 965 971
2. C.J. Bailey, P.R. Flatt, and T.W. Atkins Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice Int. J. Obes. 6 1982 11 21
3. D.J. Drucker Minireview: the glucagon-like peptides Endocrinology 142 2001 521 527
4. B.E. Dunning, and J.E. Gerich The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications Endocr. Rev. 28 2007 253 283
5. P.R. Flatt, and C.J. Bailey Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice Diabetologia 20 1981 573 577
6. Z.J. Franklin, E.P. Rafferty, N. Irwin, and F.P.M. O'Harte Peptide based glucagon analogues are effective agents in blocking the hyperglycaemic actions of glucagon in high fat fed mice Regul. Peptides 164 SI 2012 32 33
7. V.A. Gault, B.D. Kerr, N. Irwin, and P.R. Flatt C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes Biochem. Pharmacol. 75 2008 2325 2333
8. R.W. Gelling, X.Q. Du, D.S. Dichmann, J. Romer, H. Huang, L. Cui, S. Obici, B. Tang, J.J. Holst, C. Fledelius, P.B. Johansen, L. Rossetti, L.A. Jelicks, P. Serup, E. Nishimura, and M.J. Charron Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice PNAS 100 2003 1438 1443
9. B.D. Green, and P.R. Flatt Incretin hormone mimetics and analogues in diabetes therapeutics Best Pract. Res. Clin. Endocrinol. Metab. 21 2007 497 516
10. W. Gu, K.A. Winters, A.S. Motani, R. Komorowski, Y. Zhang, Q. Liu, X. Wu, I.C. Rulifson, G. Sivits Jr., M. Graham, H. Yan, P. Wang, S. Moore, T. Meng, R.A. Lindberg, and M.M. Véniant Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor Am. J. Physiol. Endocrinol. Metab. 299 2010 E624 632
11. Henquin, J.C., Accili, D., Ahrén, B., Boitard, C., Seino, S., Cerasi, E., 2011. Long in the shade, glucagon re-occupies centre court. Diabetes Obes. Metab. 13, S1:v-viii.
12. S.A. Hinke, J.A. Pospisilik, H.U. Demuth, S. Mannhart, K. Kühn-Wache, T. Hoffmann, E. Nishimura, R.A. Pederson, and C.H. McIntosh Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs J. Biol. Chem. 275 2000 3827 3834
13. J. Holst J. Henriksen, Degradation of Bioactive Substances: Physiology and Pathophysiology 1991 CRC Press, Inc. Boca Raton, FL 167 180
14. M.A. Hussain, P.B. Daniel, and J.F. Habener Glucagon stimulates expression of the inducible cAMP early repressor and suppresses insulin gene expression in pancreatic beta-cells Diabetes 49 2000 1681 1690
15. N. Irwin, K. Hunter, and P.R. Flatt Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice Peptides 29 2008 1036 1041
16. G. Jiang, and B.B. Zhang Glucagon and regulation of glucose metabolism Am. J. Physiol. Endocrinol. Metab. 284 2003 E671 678
17. B.D. Kerr, N. Irwin, P.R. Flatt, and V.A. Gault Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance Peptides 30 2009 219 225
18. B.D. Kerr, P.R. Flatt, and V.A. Gault (D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions Biochem. Pharmacol. 80 2010 1727 1735
19. R.M. Kim, J. Chang, A.R. Lins, E Brady., M.R. Candelore, Q. Dallas-Yang, V. Ding, J. Dragovic, S. Iliff, G. Jiang, S. Mock, S. Qureshi, R. Saperstein, D. Szalkowski, C. Tamvakopoulos, L. Tota, M. Wright, X. Yang, J.R. Tata, K. Chapman, B.B. Zhang, and E.R. Parmee Discovery of potent, orally active benzimidazole glucagon receptor antagonists Bioorg. Med. Chem. Lett. 18 2008 3701 3705
20. L.B. Knudsen, P.F. Nielsen, P.O. Huusfeldt, N.L. Johansen, K. Madsen, F.Z. Pedersen, H. Thøgersen, M. Wilken, and H. Agersø Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration J. Med. Chem. 43 2000 1664 1669
21. S. Lee, Y.S. Youn, S.H. Lee, Y. Byun, and K.C. Lee PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice Diabetologia 49 2006 1608 1611
22. Y. Lee, M.Y. Wang, X.Q. Du, M.J. Charron, and R.H. Unger Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice Diabetes 60 2011 391 397
23. Y. Liang, M.C. Osborne, B.P. Monia, S. Bhanot, W.A. Gaarde, C. Reed, P. She, T.L. Jetton, and K.T. Demarest Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice Diabetes 53 2004 410 417
24. N.H. McClenaghan, C.R. Barnett, E. Ah-Sing, Y.H. Abdel-Wahab, F.P. O'Harte, T.W. Yoon, S.K. Swanston-Flatt, and P.R. Flatt Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion Diabetes 45 1996 1132 1140
25. J. Mu, G. Jiang, E. Brady, Q. Dallas-Yang, F. Liu, J. Woods, E. Zycband, M. Wright, Z. Li, K. Lu, L. Zhu, X. Shen, R. Sinharoy, M.L. Candelore, S.A. Qureshi, D.M. Shen, F. Zhang, E.R. Parmee, and B.B. Zhang Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice Diabetologia 54 2011 2381 2391
26. R.L. Rodgers Glucagon and cyclic AMP: time to turn the page? Curr. Diabetes Rev. 8 2012 362 381
27. K.W. Sloop, J.X. Cao, A.M. Siesky, H.Y. Zhang, D.M. Bodenmiller, A.L. Cox, S.J. Jacobs, J.S. Moyers, R.A. Owens, A.D. Showalter, M.B. Brenner, A. Raap, J. Gromada, B.R. Berridge, D.K. Monteith, N. Porksen, R.A. McKay, B.P. Monia, S. Bhanot, L.M. Watts, and M.D. Michael Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors J. Clin. Invest. 113 2004 1571 1581
28. N.S. Sturm, Y. Lin, S.K. Burley, J.L. Krstenansky, J.M. Ahn, B.Y. Azizeh, D. Trivedi, and V.J. Hruby Structure-function studies on positions 17, 18, and 21 replacement analogues of glucagon: the importance of charged residues and salt bridges in glucagon biological activity J. Med. Chem. 41 1998 2693 2700
29. R.H. Unger, and L. Orci Glucagon and the A cell: physiology and pathophysiology (second of two parts) New Engl. J. Med. 304 1981 1575 1580
30. 9]glucagon amide, a glucagon antagonist Peptides 10 1989 1171 1177
31. C.G. Unson, C.R. Wu, K.J. Fitzpatrick, and R.B. Merrifield Multiple-site replacement analogs of glucagon. A molecular basis for antagonist design J. Biol. Chem. 269 1994 12548 12551
32. C.G. Unson, C.R. Wu, C.P. Cheung, and R.B. Merrifield Positively charged residues at positions 12, 17, and 18 of glucagon ensure maximum biological potency J. Biol. Chem. 273 1998 10308 10312
33. N.M. Whalley, L.E. Pritchard, D.M. Smith, and A. White Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells? J. Endocrinol. 211 2011 99 106
34. R.D. Wideman, S.D. Covey, G.C. Webb, D.J. Drucker, and T.J. Kieffer A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alpha-cells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice Diabetes 56 2007 2744 2752
35. M.S. Winzell, C.L. Brand, N. Wierup, U.G. Sidelmann, F. Sundler, E. Nishimura, and B. Ahrén Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet Diabetologia 50 2007 1453 1462
36. Y. Xiong, J. Guo, M.R. Candelore, R. Liang, C. Miller, Q. Dallas-Yang, G. Jiang, P.E. McCann, S.A. Qureshi, X. Tong, S.S. Xu, J. Shang, S.H. Vincent, L.M. Tota, M.J. Wright, X. Yang, B.B. Zhang, J.R. Tata, and E.R. Parmee Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl) carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes J. Med. Chem. 55 2012 6137 6148
37. H. Yan, W. Gu, J. Yang, V. Bi, Y. Shen, E. Lee, K.A. Winters, R. Komorowski, C. Zhang, J.J. Patel, D. Caughey, G.S. Elliott, Y.Y. Lau, J. Wang, Y.S. Li, T. Boone, R.A. Lindberg, S. Hu, and M.M. Véniant Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys J. Pharmacol. Exp. Ther. 329 2009 102 111